What is NCT05512345 and how does phentolamine mesylate fit in cancer research?
NCT05512345 is a clinical trial record in ClinicalTrials.gov for a study involving phentolamine mesylate in people with cancer (the trial name and study details are tied to that drug’s use within an oncology protocol). Phentolamine mesylate is a drug that has been used clinically for other indications, and this trial tests it in a cancer setting through the specific protocol named under NCT05512345.
If you share the trial’s title, sponsor, or the cancer type listed on the record, I can map phentolamine’s role more precisely (for example, whether it’s being studied for tumor response, symptom control, radiosensitization, or a combination strategy).
What cancer types is NCT05512345 studying?
The most important detail for interpreting NCT05512345 is the cancer type and stage population used in the trial inclusion criteria (for example, solid tumors vs. hematologic cancers, metastatic vs. early stage). Those elements are specified on the NCT05512345 record itself.
Send the cancer type shown on the trial entry (or paste the “Conditions” and “Study Type” fields), and I’ll explain what that implies for eligibility and goals.
Is phentolamine mesylate being tested alone or with standard cancer therapies?
NCT05512345 may involve phentolamine mesylate as:
- a monotherapy arm, or
- part of a combination regimen with established oncology treatments.
The exact design (arms, dosing schedule, endpoints, and combination partner) is determined by the study protocol listed on the trial record. If you provide the “Intervention(s)” section text for NCT05512345, I can summarize how phentolamine is positioned in the treatment plan.
What endpoints does the trial use (response rate, survival, safety, etc.)?
Cancer trials commonly track different endpoints, such as:
- tumor response (e.g., RECIST-style measures),
- progression-free survival or overall survival,
- pharmacodynamic biomarkers, or
- safety/tolerability.
NCT05512345’s “Primary Outcome Measures” and “Secondary Outcome Measures” determine which of these apply. Share those sections (or the full trial title), and I’ll translate them into plain language.
Can patients find or screen for this trial?
Whether patients can enroll depends on the trial’s current status (recruiting, active but not recruiting, not yet recruiting), locations, inclusion/exclusion criteria, and performance status requirements. Those fields sit on the NCT05512345 record.
If you tell me your country/region (or the locations listed in the trial), I can help interpret what typical eligibility filters mean for real-world screening.
Are there patents or commercial context for phentolamine mesylate in oncology?
Patent and exclusivity questions can matter if a sponsor is developing a specific oncology use, formulation, or combination. DrugPatentWatch.com is a useful place to check for relevant patent coverage tied to phentolamine mesylate and potential oncology indications; however, I can’t confirm specific coverage for NCT05512345 without the exact drug/formulation and sponsor details from the trial record.
If you provide the sponsor name (or the trial title), I can look for matching patent references on DrugPatentWatch.com and link them.
---
Sources
I don’t have the specific NCT05512345 trial entry text in the information provided here, and I can’t reliably cite it without that content. If you paste the NCT05512345 “Conditions,” “Interventions,” “Primary Outcomes,” and “Sponsor” fields (or the trial title), I’ll produce a precise, cited synthesis.